drugset
drugset / Trial / NCT06965569

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569 ↗

Phase 1 Completed 37 enrolled Alar Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).

Timeline

Start
2025-04-21
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ALA-3000 Unknown — Subcutaneous
Background Duloxetine Small molecule — Oral
Background Escitalopram Small molecule — Oral
Background Sertraline Small molecule — Oral
Background Venlafaxine Small molecule — Oral

Indications

No indication recorded.